参丹散结胶囊对晚期非小细胞肺癌患者化疗疗效及免疫的影响分析  

Influences of Shendan Sanjie capsule on chemotherapy effect and immune index to patients with advanced non-small cell lung cancer

作　　者：汪浙炯[1] 卜兴胜 谈潘莉[1] 孙菊琴 

机构地区：[1]浙江省中医院检验科,浙江杭州321017 [2]浙江大学医学院附属妇产科医院检验科,浙江杭州310006

出　　处：《中国生化药物杂志》2017年第5期200-202,共3页Chinese Journal of Biochemical Pharmaceutics

摘　　要：目的观察参丹散结胶囊对晚期非小细胞肺癌患者化疗疗效及免疫的影响。方法研究资料为2014年1月~2016年5月期间,浙江省中医院收治的76例晚期非小细胞肺癌患者,随机按照入院顺序编号,奇数为对照组（38例）,该组进行常规化疗治疗,偶数为观察组（38例）,于化疗期间加用参丹散结胶囊。分析2组患者化疗前后的疗效差异以及免疫差异。结果 （1）化疗后对照组CD4~＋下降、CD8~＋升高、CD4~＋/CD8~＋下降,和化疗前比,差异均有统计学意义（P〈0.05）;观察组CD4~＋、CD8~＋、CD4~＋/CD8~＋和化疗前相比,差异无统计学意义。化疗后观察组CD4~＋、CD8~＋、CD4~＋/CD8~＋均优于对照组（均P〈0.05）。（2）化疗后,对照组RR比例为36.84%,低于观察组57.89%（P〈0.05）。（3）化疗后2组中部分患者出现毒副作用,但观察组发生毒副反应比例较对照组低（P〈0.05）。结论对于非小细胞肺癌患者,参丹散结胶囊可调节患者在化疗期间的免疫力,控制化疗引起的毒副作用。Objective To observe the influences of Shendan Sanjie capsule on chemotherapy effect and immune index to patients with advanced non-small cell lung cancer.MethodsDividing 76 patients with advanced non-small cell lung cancer from department of oncology from January 2014 to May 2016,each with 38 cases.The control group recei-ved western chemotherapy,observation group received western chemotherapy with Shendan Sanjie capsule.The differences of related indicators were compared.Results①After chem-otherapy,in the control group, CD4＋decreased,CD8＋ increased and CD4＋/CD8＋ decreased,and before chemotherapy, the difference was significant（P〈0.05）.In observation group,there was no significant difference in CD4＋, CD8＋, CD4＋ / CD8＋ levels.The above indicators of observation group were better than that of control group.②After chemotherapy,RR（CR＋PR）rate of observation group were 57.89%, higher than the control group with 36.84%（P〈0.05）.③During chemotherapy,toxic side effect ratio of observation group was lower than that of the control group（P〈0.05）.ConclusionComparing Shen Dan Sanjie capsule can adjust patient immunity and reduce side effects of chemotherapy during chemotherapy.

关 键 词：参丹散结胶囊 非小细胞肺癌 化疗 免疫 

分 类 号：R734.2[医药卫生—肿瘤]